Invasive Group B Streptococcus Disease With Recurrence and in Multiples: Towards a Better Understanding of GBS Late-Onset Sepsis.
Age of Onset
Anti-Bacterial Agents
/ adverse effects
Drug-Related Side Effects and Adverse Reactions
/ epidemiology
Dysbiosis
/ epidemiology
Europe
/ epidemiology
Female
Humans
Infant, Newborn
Male
Microbiota
Pregnancy
Pregnancy Complications, Infectious
Recurrence
Retrospective Studies
Risk Factors
Sepsis
/ epidemiology
Streptococcal Infections
/ epidemiology
Streptococcus
/ physiology
Triplets
Twins
group B Streptococcus
late-onset sepsis
microbiome
multiples
recurrence
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
15
10
2020
accepted:
04
05
2021
entrez:
21
6
2021
pubmed:
22
6
2021
medline:
24
8
2021
Statut:
epublish
Résumé
Group B Streptococcus (GBS) is a common intestinal colonizer during the neonatal period, but also may cause late-onset sepsis or meningitis in up to 0.5% of otherwise healthy colonized infants after day 3 of life. Transmission routes and risk factors of this late-onset form of invasive GBS disease (iGBS) are not fully understood. Cases of iGBS with recurrence (n=25) and those occurring in parallel in twins/triplets (n=32) from the UK and Ireland (national surveillance study 2014/15) and from Germany and Switzerland (retrospective case collection) were analyzed to unravel shared (in affected multiples) or fixed (in recurrent disease) risk factors for GBS disease. The risk of iGBS among infants from multiple births was high (17%), if one infant had already developed GBS disease. The interval of onset of iGBS between siblings was 4.5 days and in recurrent cases 12.5 days. Disturbances of the individual microbiome, including persistence of infectious foci are suggested e.g. by high usage of perinatal antibiotics in mothers of affected multiples, and by the association of an increased risk of recurrence with a short term of antibiotics [aOR 4.2 (1.3-14.2), P=0.02]. Identical GBS serotypes in both recurrent infections and concurrently infected multiples might indicate a failed microbiome integration of GBS strains that are generally regarded as commensals in healthy infants. The dynamics of recurrent GBS infections or concurrent infections in multiples suggest individual patterns of exposure and fluctuations in host immunity, causing failure of natural niche occupation.
Identifiants
pubmed: 34149682
doi: 10.3389/fimmu.2021.617925
pmc: PMC8208644
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
617925Informations de copyright
Copyright © 2021 Freudenhammer, Karampatsas, Le Doare, Lander, Armann, Acero Moreno, Boyle, Buxmann, Campbell, Chalker, Cunney, Doherty, Davies, Efstratiou, Elling, Endmann, Essers, Hentschel, Jones, Kallsen, Kapatai, Krüger, Ladhani, Lamagni, Lindsay, Meehan, O’Sullivan, Patel, Reynolds, Roll, Schulzke, Smith, Stein, von der Wense, Voss, Wieg, Härtel, Heath and Henneke.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Infection. 2017 Aug;45(4):449-458
pubmed: 28236250
Arch Pediatr. 2017 Dec;24 Suppl 3:S24-S28
pubmed: 29433694
Nat Med. 2014 May;20(5):524-30
pubmed: 24747744
Arch Dis Child. 2019 Apr;104(4):401-405
pubmed: 30413494
Nat Commun. 2014 Aug 04;5:4544
pubmed: 25088811
Pediatrics. 2018 Nov;142(5):
pubmed: 30309887
Scand J Immunol. 2013 Nov;78(5):426-38
pubmed: 23809143
Lancet Infect Dis. 2019 Jan;19(1):83-90
pubmed: 30497953
Arch Dis Child Fetal Neonatal Ed. 2014 Jan;99(1):F41-7
pubmed: 23955469
J Appl Microbiol. 2015 Apr;118(4):1034-47
pubmed: 25786121
J Infect. 2017 Jun;74 Suppl 1:S34-S40
pubmed: 28646960
Pediatr Infect Dis J. 1991 Aug;10(8):621-3
pubmed: 1891294
Clin Infect Dis. 2017 Nov 6;65(suppl_2):S200-S219
pubmed: 29117332
Clin Dev Immunol. 2012;2012:985646
pubmed: 22235228
Appl Microbiol Biotechnol. 2014 Jul;98(13):6051-60
pubmed: 24687755
Pediatrics. 2019 Aug;144(2):
pubmed: 31285392
Pediatr Infect Dis J. 2014 Apr;33(4):428
pubmed: 24632666
Nature. 2017 Aug 24;548(7668):407-412
pubmed: 28813414
Sci Rep. 2019 Jul 23;9(1):10635
pubmed: 31337807
Clin Infect Dis. 2019 Oct 30;69(10):1740-1748
pubmed: 30946447
J Infect Dis. 2003 Jul 15;188(2):267-71
pubmed: 12854082
Clin Infect Dis. 2009 Nov 1;49(9):1393-6
pubmed: 19814626
Lancet Infect Dis. 2014 Nov;14(11):1083-1089
pubmed: 25444407
Infect Dis Rep. 2018 Dec 05;10(3):7744
pubmed: 30662690
J Pediatr. 2013 Oct;163(4):1099-104.e1
pubmed: 23866714
Front Immunol. 2017 Nov 10;8:1497
pubmed: 29209311
Sci Rep. 2017 Nov 28;7(1):16527
pubmed: 29184093
Obstet Gynaecol. 2018 Jan;20(1):57-63
pubmed: 30008614
Clin Infect Dis. 2017 Nov 6;65(suppl_2):S160-S172
pubmed: 29117326
Pediatrics. 2014 May;133(5):e1388-91
pubmed: 24709927
Clin Infect Dis. 2017 Nov 6;65(suppl_2):S190-S199
pubmed: 29117331
Front Immunol. 2018 Feb 28;9:361
pubmed: 29599768
J Pediatr. 2013 Jun;162(6):1120-4, 1124.e1
pubmed: 23324523
Clin Infect Dis. 2014 May;58(9):1211-8
pubmed: 24647013
Clin Microbiol Infect. 2011 Sep;17(9):1294-303
pubmed: 21672083
Clin Infect Dis. 2017 Nov 6;65(suppl_2):S143-S151
pubmed: 29117324
JAMA Pediatr. 2019 Mar 1;173(3):224-233
pubmed: 30640366
Pediatrics. 1999 Jun;103(6):e77
pubmed: 10353974